Back to Search Start Over

Transcriptomic Profile Identified a Specific Signature in Children with Acute Myeloid Leukemia (AML) and Primary Induction Failure (PIF): Preliminary Data and Future Perspectives

Authors :
Lo Nigro, Luca
Barresi, Vincenza
Andriano, Nellina
Pulvirenti, Giulio
Spampinato, Giorgia
Bonaccorso, Paola
Iachelli, Valeria
La Rosa, Manuela
Cannata, Emanuela
Di Cataldo, Andrea
Russo, Giovanna
Condorelli, Daniele
Source :
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p5280-5280, 1p
Publication Year :
2018

Abstract

Background.Acute Myeloid Leukemia is a heterogeneous disease, characterized by the uncontrolled proliferation of hematopoietic precursor cells. AML accounts for 15% of acute leukemias in children, with a cure rate of 55-60% as overall survival (Pession A Blood 2013). Complete remission (CR) is achieved in 80-85% of children with AML. Current protocol defines CR by morphological evaluation (blasts <5%) and cytofluorimetric analyses (blasts <0,1%), after two cycles of high-dose chemotherapy. Around 10-15% of children and 30% of adults do not achieve remission and are defined as Primary Induction Failure (PIF). The majority of these cases are addressed to other form of high-dose chemotherapy blocks, experimental therapies or directly to hematopoietic stem cell transplantation (HSCT) as salvage treatment, showing a very poor prognosis (Quarello P et al. British Journal of Haematology 2015). Strong efforts to generate biological data in order to define this subtype of AML are needed for early identification and for target therapy design.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
132
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56521720
Full Text :
https://doi.org/10.1182/blood-2018-99-116093